Afaneh Cheguevara, Abelson Jonathan, Schattner Mark, Janjigian Yelena Y, Ilson David, Yoon Sam S, Strong Vivian E
Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
Ann Surg Oncol. 2015 Apr;22(4):1252-7. doi: 10.1245/s10434-014-4125-4. Epub 2014 Oct 16.
Esophagojejunal (EJ) anastomotic leaks after total gastrectomy (TG) for malignancy lead to significant morbidity and mortality, thus affecting long-term survival. Preclinical and clinical trials have shown promise in utilizing degradable extracellular matrix (ECM) scaffolds in buttressing anastomoses. We describe our experience buttressing the EJ anastomosis after TG with a ECM scaffold.
From February 2012 to January 2014, a total of 37 consecutive patients underwent TG buttressing of the EJ anastomosis with the degradable ECM scaffold composed of a porcine urinary bladder called MatriStem (ACell Inc.). The scaffold was circumferentially wrapped around the EJ anastomosis. The primary end point was the EJ leak rate, while the secondary end point was the EJ stricture rate.
The mean ± SD age and body mass index were 59 ± 16 years and 28.1 ± 4.9 kg/m(2), respectively. Most patients were male (51 %), white (78 %), and former smokers (51 %). Over half (59 %) underwent neoadjuvant chemotherapy. A minimally invasive TG was performed in 70 % of patients. Signet ring was the most common tumor type (48 %), and most patients had midstage disease (59 %). The mean number of lymph nodes procured was 36 ± 16. Eighteen patients (49 %) experienced a complication, mostly minor. One patient (2.7 %) developed an EJ leak, while three patients (8 %) developed an EJ stricture. Median follow-up was 7 months (range 2-12 months). There was no operative or in-hospital mortality.
The use of urinary bladder matrix scaffolds may be helpful in decreasing the incidence of EJ anastomotic leak and/or stricture. A prospective phase II trial at our institution is currently under way.
恶性肿瘤全胃切除术后的食管空肠(EJ)吻合口漏会导致显著的发病率和死亡率,从而影响长期生存。临床前和临床试验已显示出利用可降解细胞外基质(ECM)支架加强吻合术的前景。我们描述了使用ECM支架加强全胃切除术后EJ吻合术的经验。
2012年2月至2014年1月,共有37例连续患者接受了使用由猪膀胱制成的名为MatriStem(ACell公司)的可降解ECM支架加强EJ吻合术的全胃切除术。该支架沿圆周方向包裹在EJ吻合口周围。主要终点是EJ漏率,次要终点是EJ狭窄率。
平均年龄±标准差和体重指数分别为59±16岁和28.1±4.9kg/m²。大多数患者为男性(51%)、白人(78%)且为既往吸烟者(51%)。超过一半(59%)的患者接受了新辅助化疗。70%的患者接受了微创全胃切除术。印戒细胞是最常见的肿瘤类型(48%),大多数患者处于疾病中期(59%)。获取的淋巴结平均数量为36±16个。18例患者(49%)出现并发症,大多为轻微并发症。1例患者(2.7%)发生EJ漏,3例患者(8%)发生EJ狭窄。中位随访时间为7个月(范围为2 - 12个月)。无手术或住院期间死亡。
使用膀胱基质支架可能有助于降低EJ吻合口漏和/或狭窄的发生率。我们机构目前正在进行一项前瞻性II期试验。